Verastem Oncology drops despite Q3 double beat

3 hours ago 1

Verastem Oncology (VSTM) is down ~17% in Tuesday trading despite reporting Q3 financial results that beat on both lines.
While it isn't clear what is leading the decline, in the quarter, Verastem saw a significant year-over-year increase in operating costs, along with a $26M cash